Related Experiment Video
Updated: Dec 21, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
P53: A Guardian of Immunity Becomes Its Saboteur through Mutation
Arjelle Decasa Agupitan1, Paul Neeson2,3, Scott Williams4
1Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia.
Abstract:
Awareness of the importance of immunity in controlling cancer development triggered research into the impact of its key oncogenic drivers on the immune response, as well as their value as targets for immunotherapy. At the heart of tumour suppression is p53, which was discovered in the context of viral infection and now emerges as a significant player in normal and cancer immunity. Wild-type p53 (wt p53) plays fundamental roles in cancer immunity and inflammation. Mutations in p53 not only cripple wt p53 immune functions but also sinisterly subvert the immune function through its neomorphic gain-of-functions (GOFs). The prevalence of mutant p53 across different types of human cancers, which are associated with inflammatory and immune dysfunction, further implicates mutant p53 in modulating cancer immunity, thereby promoting tumorigenesis, metastasis and invasion. In this review, we discuss several mutant p53 immune GOFs in the context of the established roles of wt p53 in regulating and responding to tumour-associated inflammation, and regulating innate and adaptive immunity. We discuss the capacity of mutant p53 to alter the tumour milieu to support immune dysfunction, modulate toll-like receptor (TLR) signalling pathways to disrupt innate immunity and subvert cell-mediated immunity in favour of immune privilege and survival. Furthermore, we expose the potential and challenges associated with mutant p53 as a cancer immunotherapy target and underscore existing therapies that may benefit from inquiry into cancer p53 status.
Insights
Mutant p53 proteins, common in cancers, disrupt normal immune responses and promote tumor growth. Targeting these mutant p53 gain-of-functions offers a promising new avenue for cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The tumor suppressor protein p53 (also known as p53) is crucial for controlling cancer development and is increasingly recognized for its role in immunity.
- Wild-type p53 (wt p53) regulates inflammation and both innate and adaptive immune responses.
- Mutations in p53 are prevalent in human cancers and are linked to immune dysfunction.
Purpose of the Study:
- To review the impact of oncogenic drivers, specifically mutant p53, on cancer immunity.
- To discuss the neomorphic gain-of-functions (GOFs) of mutant p53 that subvert immune function.
- To explore mutant p53 as a potential target for cancer immunotherapy.
Main Methods:
- Literature review focusing on the roles of wild-type and mutant p53 in cancer immunity.
- Analysis of mutant p53's impact on tumor microenvironment, inflammation, and immune signaling pathways (e.g., toll-like receptor signaling).
- Discussion of immune evasion mechanisms mediated by mutant p53.
Main Results:
- Mutant p53 cripples wt p53's immune functions and promotes tumorigenesis, metastasis, and invasion.
- Mutant p53 alters the tumor microenvironment to foster immune dysfunction.
- Mutant p53 disrupts innate immunity via toll-like receptor pathways and promotes immune privilege by subverting cell-mediated immunity.
Conclusions:
- Mutant p53 plays a significant role in modulating cancer immunity, often promoting immune evasion.
- Targeting mutant p53's immune GOFs presents a potential strategy for cancer immunotherapy.
- Existing therapies may be enhanced by considering the p53 mutational status of cancers.
Related Concept Videos
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Negative Regulator Molecules

